FGFR2 testing for patients with CCA is publicly funded in Ontario, Alberta, and Quebec and is otherwise available via various research programs, highlighting a disconnect between the funding approaches to biomarker testing and their associated therapies. Here, FGFR2 is linked to cholangiocarcinoma.